Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients: the LiverT...

Area of Science:

• Hepatology
• Oncology
• Clinical Research

Background:

• Transarterial chemoembolization (TACE) is a common treatment for hepatocellular carcinoma (HCC).
• The real-world incidence and impact of chronic liver damage following TACE are not well-established.
• This study investigates liver function changes after TACE in a US patient cohort.

Purpose of the Study:

• To assess the real-world incidence of liver function deterioration after a single TACE procedure in HCC patients.
• To identify clinically meaningful changes in liver function laboratory parameters post-TACE.
• To evaluate the persistence of liver function deterioration in the chronic phase after TACE.

Main Methods:

• Retrospective observational study using a real-world US claims database (Optum).
• Identified HCC patients who underwent a single TACE between 2010 and 2016.
• Analyzed laboratory values (bilirubin, albumin, AST, ALT, INR) at baseline, acute (≤29 days), and chronic (30-90 days) periods post-TACE.

Main Results:

• Of 3963 TACE patients, 572 met eligibility criteria.
• Significant liver function deterioration observed in the acute period, persisting into the chronic period for bilirubin, albumin, AST, ALT, and INR.
• Patients with diabetes showed a higher proportion of AST and ALT deterioration.

Conclusions:

• A clinically meaningful proportion of HCC patients experience liver function deterioration 30-90 days after TACE.
• Findings underscore the importance of careful patient selection for TACE to optimize treatment outcomes.
• Further EHR research is suggested to establish causality of liver function changes post-TACE.